Diarrhoea News and Research RSS Feed - Diarrhoea News and Research

Experts call for action to prevent health risks associated with climate change

Experts call for action to prevent health risks associated with climate change

Previously unrecognized health benefits could be realized from fast action to reduce climate change and its consequences. For example, changes in energy and transport policies could save millions of lives annually from diseases caused by high levels of air pollution. The right energy and transport policies could also reduce the burden of disease associated with physical inactivity and traffic injury. [More]
Genetic changes in patients with Crohn's disease could hold clues to fighting illness

Genetic changes in patients with Crohn's disease could hold clues to fighting illness

Genetic changes that occur in patients with the bowel condition Crohn's disease could hold clues to fighting the illness. [More]
First-line sunitinib superior to everolimus for metastatic RCC

First-line sunitinib superior to everolimus for metastatic RCC

Results for the RECORD-3 trial support the current strategy of first-line sunitinib followed by second-line everolimus for the treatment of patients with metastatic renal cell carcinoma. [More]
Families affected by conflict in Syria receive parenting advice from experts

Families affected by conflict in Syria receive parenting advice from experts

Families living in and affected by the conflict in Syria have been receiving parenting advice from experts at The University of Manchester via a daily bread delivery service. [More]
Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

Drugs widely prescribed to the elderly could be responsible for a decline in cognitive and physical function according to research from the University of East Anglia and the Regenstrief Institute. [More]
EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union. [More]
Forecast report on Global Ovarian Cancer market

Forecast report on Global Ovarian Cancer market

Research and Markets has announced the addition of the "Global Ovarian Cancer Market 2014-2018" report to their offering. [More]
Simple and hygienic measures can prevent campylobacter infections

Simple and hygienic measures can prevent campylobacter infections

In Switzerland, between 7000 and 8000 persons fall ill with a campylobacter infection annually. This makes it the most frequent bacterial disease transmitted through food. [More]
New estimates highlight the importance of developing norovirus vaccines

New estimates highlight the importance of developing norovirus vaccines

Noroviruses are a leading cause of acute gastroenteritis (diarrhoea and vomiting) across all age groups, responsible for almost a fifth (18%) of all cases worldwide. New estimates, published in The Lancet Infectious Diseases, highlight the importance of developing norovirus vaccines, say the authors. [More]
Noroviruses responsible for almost a fifth of all cases of acute gastroenteritis

Noroviruses responsible for almost a fifth of all cases of acute gastroenteritis

Noroviruses are a leading cause of acute gastroenteritis (diarrhoea and vomiting) across all age groups, responsible for almost a fifth (18%) of all cases worldwide. New estimates, published in The Lancet Infectious Diseases, highlight the importance of developing norovirus vaccines, say the authors. [More]
Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer in patients with wild-type epidermal growth-factor receptor tumour status. [More]
Review on effects of treating cholera with antimicrobial drugs

Review on effects of treating cholera with antimicrobial drugs

Researchers from the Cochrane Infectious Diseases Group, co-ordinated through the editorial base in LSTM, conducted an independent review of the effects of treating cholera with antimicrobial drugs, published in The Cochrane Library today. [More]
New device designed to detect foodborne bacteria

New device designed to detect foodborne bacteria

A new device designed to sample and detect foodborne bacteria is being trialled by scientists at the University of Southampton. [More]
Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Many people with cystic fibrosis develop diabetes. The reasons for this
have been largely unknown, but now researchers at Lund University in Sweden and
 Karolinska institutet have identified a molecular mechanism that contributes to
the raised diabetes risk. [More]
Biótica researchers develop automated laboratory system that rapidly detects E. coli bacterium

Biótica researchers develop automated laboratory system that rapidly detects E. coli bacterium

A Castellón-based biotechnology R&D project by Biótica has been successfully certified by the Centre for Technological and Industrial Development (CDTI, in Spanish), of the Spanish Ministry of Economy and Competitiveness. [More]
Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). [More]
Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer. [More]
Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study. [More]
Depression is the leading cause of illness in adolescents, shows WHO's report

Depression is the leading cause of illness in adolescents, shows WHO's report

WHO's "Health for the world's adolescents" report reveals that depression is the predominant cause of illness and disability for both boys and girls aged 10 to 19 years. [More]